JNNP: Clinically isolated syndrome, higher rates of death and disability in patients with brain atrophy

Multiple sclerosis (MS) is a chronic inflammation, demyelination and neurodegenerative disease of the central nervous system.
About 85% of patients with multiple sclerosis are initially relapsing-remitting (RR) multiple sclerosis.
The accumulation of inflammatory demyelinating disease is related, but in the long term, most people develop secondary progressive (SP) multiple sclerosis.

Multiple sclerosis (MS) is a chronic inflammation, demyelination and neurodegenerative disease of the central nervous system.
About 85% of patients with multiple sclerosis are initially relapsing-remitting (RR) multiple sclerosis.
The accumulation of inflammatory demyelinating disease is related, but in the long term, most people develop secondary progressive (SP) multiple sclerosis.

Neurodegeneration is considered to be the main cause of irreversible disability, and also the main related factor of brain atrophy measured by MRI in vivo.
Although brain atrophy occurs very early in the course of MS, and SPMS patients seem to have faster brain atrophy compared with RRMS, it is still unknown when it will become clinically relevant.

Neurodegeneration is considered to be the main cause of irreversible disability, and also the main related factor of brain atrophy measured by MRI in vivo.
Although brain atrophy occurs very early in the course of MS, and SPMS patients seem to have faster brain atrophy compared with RRMS, it is still unknown when it will become clinically relevant.

In particular, it is currently unclear whether early brain atrophy is significantly associated with long-term clinical outcomes and can accordingly represent an early treatment goal.

In particular, it is currently unclear whether early brain atrophy is significantly associated with long-term clinical outcomes and can accordingly represent an early treatment goal.

In this way, Lukas Haider and others of UCL in the United Kingdom completed a 30-year longitudinal, clinical and MRI follow-up study.
The study object was a cohort recruited shortly after Clinical Isolated Syndrome (CIS).
CIS often means MS.
Of the 120 people with known results (out of the 132 initially recruited), one-third are still classified as having CIS, one-third develop SPMS or MS resulting in death, and the remaining people have RRMS, of which about 90% of people can walk without restriction due to MS.
Early accumulation of white matter lesions (WML), especially submeningeal and deep WML within the first year, and disability within the first 5 years, and the development of SPMS or MS within 30 years And death is significantly related.

In this way, Lukas Haider and others of UCL in the United Kingdom completed a 30-year longitudinal, clinical and MRI follow-up study.
The study object was a cohort recruited shortly after Clinical Isolated Syndrome (CIS).
CIS often means MS.
Of the 120 people with known results (out of the 132 initially recruited), one-third are still classified as having CIS, one-third develop SPMS or MS resulting in death, and the remaining people have RRMS, of which about 90% of people can walk without restriction due to MS.
Early accumulation of white matter lesions (WML), especially submeningeal and deep WML within the first year, and disability within the first 5 years, and the development of SPMS or MS within 30 years And death is significantly related.

In this latest study, they explored the brain atrophy rate 30 years after clinical isolation syndrome, and the relationship between the atrophy in the first 5 years and the clinical outcome 25 years later.

In this latest study, they explored the brain atrophy rate 30 years after clinical isolation syndrome, and the relationship between the atrophy in the first 5 years and the clinical outcome 25 years later.

They recruited 132 people with clinically isolated syndromes suggesting multiple sclerosis (MS) between 1984 and 1987.
For 30 years, clinical and MRI data have been collected prospectively.
The width of the third ventricle and the medulla oblongata was used as a measure of linear atrophy.

They recruited 132 people with clinically isolated syndromes suggesting multiple sclerosis (MS) between 1984 and 1987.
For 30 years, clinical and MRI data have been collected prospectively.
The width of the third ventricle and the medulla oblongata was used as a measure of linear atrophy.

They found that at the 30th year, 27 participants were still classified as having clinically isolated syndrome, 34 were converted to relapsing-remitting MS, 26 were converted to secondary progressive MS, and 16 had died of MS .

They found that at the 30th year, 27 participants were still classified as having clinically isolated syndrome, 34 were converted to relapsing-remitting MS, 26 were converted to secondary progressive MS, and 16 had died of MS .

The mean age at baseline was 31.
7 years (SD 7.
5), and the mean duration of illness was 30.
8 years (SD 0.
9).
The changes in the width of the medulla and third ventricle within the first 5 years allow the increase in the white matter lesions involving the extended disability status scale over the same period, predicting the clinical outcome measurement at 30 years.
Using logistic regression, the medulla atrophy was 1mm in the first 5 years, and the risk of secondary progressive MS or MS-related death within 30 years increased by 583% (OR 5.
83, 95% CI 1.
74-19.
61, P<0.
005).

The mean age at baseline was 31.
7 years (SD 7.
5), and the mean duration of illness was 30.
8 years (SD 0.
9).
The changes in the width of the medulla and third ventricle within the first 5 years allow the increase in the white matter lesions involving the extended disability status scale over the same period, predicting the clinical outcome measurement at 30 years.
Using logistic regression, the medulla atrophy was 1mm in the first 5 years, and the risk of secondary progressive MS or MS-related death within 30 years increased by 583% (OR 5.
83, 95% CI 1.
74-19.
61, P<0.
005).

The significance of this study is that brain region atrophy within 5 years of clinically isolated syndrome can predict progressive MS or related death, and disability after 25 years.

The significance of this study is that brain region atrophy within 5 years of clinically isolated syndrome can predict progressive MS or related death, and disability after 25 years.

Original source:

Original source:

bmj.

com/content/early/2021/03/29/jnnp-2020-325421" target="_blank" rel="noopener">Haider, L.
, Chung, K.

bmj.
com/content/early/2021/03/29/jnnp-2020-325421" target="_blank" rel="noopener">Haider, L.
, Chung, K.
, Birch, G.
, Eshaghi, A.
, Mangesius, S.
, Prados, F.
, .
.
.
& Chard, D.
(2021).
Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up.
_Journal of Neurology, Neurosurgery & Psychiatry_.
bmj.
com/content/early/2021/03/29/jnnp-2020-325421" target="_blank" rel="noopener"> Haider, L.
, Chung, K.
, Birch, G.
, Eshaghi, A.
, Mangesius, S.
, Prados, F.
, .
.
.
& Chard, D.
(2021).
Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up.
_Journal of Neurology, Neurosurgery & Psychiatry_.
Leave a message here